Intellia.jpg
Intellia Therapeutics Announces First Quarter 2021 Financial Results
May 06, 2021 07:30 ET | Intellia Therapeutics, Inc.
Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND...
22157.jpg
Outlook on the Cell Therapy Global Market to 2027 - by Therapy Type, Product, Technology, Application, End-user and Geography
March 31, 2021 05:18 ET | Research and Markets
Dublin, March 31, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapy Type; Product; Technology; Application; End User, and Geography"...
Intellia.jpg
Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
March 30, 2021 07:30 ET | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
22157.jpg
Global Precision Medicine Market (2021 to 2028) - Demand for Preventive Care Presents Opportunities
March 25, 2021 08:13 ET | Research and Markets
Dublin, March 25, 2021 (GLOBE NEWSWIRE) -- The "Global Precision Medicine Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The publisher predicts that the global market...
Intellia.jpg
Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
March 25, 2021 07:30 ET | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at...
22157.jpg
North America Digital Genome Market Report 2021: Continuous Funding by the Manufacturers and Government in the Field of Genomics - Forecast to 2028
March 15, 2021 06:03 ET | Research and Markets
Dublin, March 15, 2021 (GLOBE NEWSWIRE) -- The "North America Digital Genome Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. North America market for digital genome is...
22157.jpg
Outlook on the Cell Therapy Biomanufacturing Global Market to 2025 - by Product Type, Application and Region
February 22, 2021 06:48 ET | Research and Markets
Dublin, Feb. 22, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Biomanufacturing: Global Markets" report has been added to ResearchAndMarkets.com's offering. This research report presents an in-depth...
22157.jpg
Global Gene Therapy Market Outlook to 2030 - by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration and Key Geographical Regions
February 15, 2021 07:03 ET | Research and Markets
Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration, and Key...
22157.jpg
Outlook on the CRISPR Gene Editing Global Market to 2030 - Analysis and Forecasts
February 08, 2021 07:33 ET | Research and Markets
Dublin, Feb. 08, 2021 (GLOBE NEWSWIRE) -- The "Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and...
Intellia.jpg
Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency
December 12, 2020 09:00 ET | Intellia Therapeutics, Inc.
Demonstrates modularity of Intellia’s in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy Single-course administration of genome editing system...